CLOs on the Move

Vertex Pharmaceuticals

www.vrtx.com

 
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.vrtx.com
  • 50 Northern Avenue
    Boston, MA USA 02210
  • Phone: 617.341.6100

Executives

Name Title Contact Details
Evan Panich
Sr. Counsel Profile
John Lally
Vice President, Commercial, Patient and External Affairs Technology Profile
Brian Barry
Vice President, Chief Compliance Officer Profile
Jennifer DiFruscio
Assistant General Counsel Profile
Michael Bullard
Director and Senior Counsel Profile

Similar Companies

Biovista

Biovista is a Charlottesville, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Verinata Health

Verinata Health is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioE

BioE is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Reprocell

Reprocell is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Metacrine

We are a clinical-stage biopharmaceutical company focused on discovering and developing best-in-class therapies for patients with liver and gastrointestinal, or GI, diseases. Since our founding in 2014, we have invested in building a foundation of chemistry and biology expertise to drive innovative drug discovery and development. We believe these internal capabilities allow us to gain insights into disease targets and mechanisms and more quickly and purposefully design therapies with characteristics that we view as key to safety and efficacy. With this systematic approach, we have designed novel, proprietary farnesoid X receptor (FXR) clinical product candidates arising from a unique chemical scaffold with the potential to be best-in-class for non-alcoholic steatohepatitis, or NASH, and first- in-class for Inflammatory Bowel Disease, or IBD. In addition to our FXR program, we have continued to invest in drug discovery on other therapeutic targets that have effects on inflammation and/or fibrosis for which we believe we could develop proprietary small molecule therapies.